Constitutional Amendment update

The two constitutional amendments also on the ballot papers were also heavily supported but unfortunately not enough members voted to meet the 66% of current membership rule.

The executive have decided to put these two amendments to the membership again early in the new year and encourage all members to ensure they cast their vote.

ICORG becomes an all-Ireland entity

Following discussions with the leaders of the Northern Ireland Clinical Trials Unit in March of this year and culminating with a meeting in May in Dublin, ICORG became an all-Ireland organisation. This resulted in an increase in the membership in recent months of 21 consultants from north of the border.

ICORG membership grows to 126

The ICORG membership has grown steadily since its inaugral roster of 32 back in October 1996 and is now 126. The recent growth has been due mainly to the addition of members from north of the border.

Irish Cancer Society decide to provide more substantial funding for the ICORG central office

Following discussions with the Irish Cancer Society (ICS) in the early part of 2000, and representations made to the board on ICORGs behalf by John Crown, John Armstrong and John Kennedy the board of the society have decided to increase the ICORG central office annual funding substantially. The executive of ICORG are very grateful to the ICS for this essential support.

97-01 long v short hormone treatment of prostate passes 200 mark

This study is an indication of what Irish investigators can achieve when they work together. It will be a unique achievement when completed in the final quarter of 2001. It will be an Irish designed study set up to answer an important clinical question fully completed in Ireland. In November of this year it enrolled its 200 patient, the target of 260 patients will be reached in the fourth quarter or earlier.

98-01 B.I.G node positive breast study passes 100 Irish patients mark

During the week of the 6th of November the 100th Irish Patient was enrolled into the B.I.G. node positive study. This is the first time that a multi-national oncology study has accrued 100 Irish patients and must auger well for the future of ICORG and oncology clinical research in Ireland. This achievement is all the more important in light of the fact that this is the first multi-national study that is co-chaired by ICORG. It will help strengthen the ICORG negotiation position when discussing future key projects with companies or collaborative groups. Study has been extended to 2700 patients (ending May 2001 approx.) Ireland has one of the best accrual rates in Europe. SVUH 2nd highest accruing site out of 188 sites worldwide.

Lung abstract ASCO 1999

ASCO abstracts (99 – Lung, 00 – 2 NHL)
ICORG is very proud to announce that the 97-03 lung study was chosen to be presented in poster format at ASCO 1999 in Atlanta, this is a considerable achievement in view of the fact that less than 100 abstracts were chosen out of a total of more than 600 submissions.

New oncology research staff appointed in Galway Cork and Waterford

In line with the growth in the quantity of oncology clinical research in Ireland in the last two years, the number of active sites, the number of protocols open and the number of patients accrued on to these studies there have been a number of new research co-ordinator’s appointed.

IMB Auditing Most commonly made mistakes in Ireland

The ICORG central office have been involved to lesser or greater extent in 5 IMB audits, the most common errors found can be discussed with the ICORG central office. All audits were passed without critical findings.

An extensive list of the most common errors will be posted on the site in the near future.

2 ICORG study sites pass Irish Medicines Board GCP Audit

Two ICORG sites past Irish Medicines Board audit: There is a new initiative by the Irish Medicines Board to audit a percentage of the most active Irish investigators each year. This started in 1999. Two ICORG study sites were chosen for review in the first year. The audit possibility has always been available to the Irish Medicines Board in the past but for a variety of reasons has not been enforced prior to 1999.